Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin,...
Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax.
From other sites
Video at CNBC.com (Wed, 5:40PM)
Video at CNBC.com (Wed, 3:13PM)
Video at CNBC.com (Nov 24, 2015)
Video at CNBC.com (Sep 30, 2015)
Video at CNBC.com (Aug 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs